HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GLPG2222

C1 corrector

Also Known As:

4-((2R,4R)-4-(((1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl)carbonyl)amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl)benzoic acid; ABBV-2222

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Greszler, Stephen N: 2 articles (09/2021 - 01/2019)
2.	Kym, Philip R: 2 articles (09/2021 - 01/2020)
3.	Voight, Eric A: 2 articles (09/2021 - 01/2019)
4.	Alani, Sara: 1 article (01/2020)
5.	Balut, Corina: 1 article (01/2020)
6.	Conrath, Katja: 1 article (01/2020)
7.	Cyr, Douglas: 1 article (01/2020)
8.	Fan, Yihong: 1 article (01/2020)
9.	Gao, Wenqing: 1 article (01/2020)
10.	Hwang, Tzyh-Chang: 1 article (01/2020)

Related Diseases

1.	Cystic Fibrosis (Mucoviscidosis) 01/01/2019 - "An enabling preclinical synthetic route to cystic fibrosis candidate ABBV-2222 is described. " 01/01/2019 - "Enabling Synthesis of ABBV-2222, A CFTR Corrector for the Treatment of Cystic Fibrosis." 09/09/2021 - "In the first ten years of innovative science in pursuit of excellence in synthesis, several advanced drug candidates, including ABBV-2222 (galicaftor) for cystic fibrosis and foslevodopa/foscarbidopa for Parkinson's disease, have emerged with key contributions from COS." 01/01/2020 - "ABBV-2222/GLPG2222 exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 value <10 nM. SIGNIFICANCE STATEMENT: To address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in cystic fibrosis, AbbVie-Galapagos has developed ABBV-2222/GLPG2222, a novel, potent, and orally bioavailable C1 corrector of this protein. "
2.	Parkinson Disease (Parkinson's Disease) 09/09/2021 - "In the first ten years of innovative science in pursuit of excellence in synthesis, several advanced drug candidates, including ABBV-2222 (galicaftor) for cystic fibrosis and foslevodopa/foscarbidopa for Parkinson's disease, have emerged with key contributions from COS."

Related Drugs and Biologics

1.	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)
2.	Proteins (Proteins, Gene)